Treatment of hepatocellular carcinoma cells with EGCG causes an inhibition of the expression and activity of phosphofructokinase and anti‐apoptotic protein B‐cell lymphoma2 (Bcl‐2), which facilitates apoptosis [28]. This evidence concerns the gene BCL2 and hepatocellular carcinoma.